One-year results of the ICON (ionic versus non-ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients) Study
| Autor: | William E. Downey, Peter J. Casterella, Ioannis Mastoris, Eugenia Nikolsky, Usman Baber, George Dangas, Paul S. Teirstein, Kleanthis Theodoropoulos, Georgios J. Vlachojannis, Roxana Mehran, Wayne B. Batchelor, Jennifer Yu, S. Chiu Wong, Gennaro Giustino |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Mortality rate Percutaneous coronary intervention General Medicine 030204 cardiovascular system & hematology Revascularization medicine.disease Iodixanol Surgery 03 medical and health sciences 0302 clinical medicine Angioplasty Internal medicine Cardiology Medicine Radiology Nuclear Medicine and imaging 030212 general & internal medicine Myocardial infarction Cardiology and Cardiovascular Medicine business medicine.drug Cardiac catheterization Kidney disease |
| Zdroj: | Catheterization and Cardiovascular Interventions. 87:703-709 |
| ISSN: | 1522-1946 |
| DOI: | 10.1002/ccd.26106 |
| Popis: | Background Long-term clinical outcomes after exposure to non-ionic iso-osmolar contrast medium (IOCM) or ionic low-osmolar CM (LOCM) in patients with chronic kidney disease (CKD) undergoing coronary angiography are unclear. Methods The ICON trial was a prospective, double-blinded, multicentre study that randomly assigned 146 patients with CKD undergoing coronary angiography with or without percutaneous coronary intervention to the non-ionic IOCM Iodixanol or the ionic LOCM Ioxaglate. We report the 1-year clinical outcomes. Results After randomization, baseline and procedural characteristics were well-matched between the two groups. At 1 year, three deaths (4.1%) occurred in the ioxaglate and nine deaths in the iodixanol group (13.6%, P = 0.07). The cardiac death rate at 1 year was 2.7% in the ioxaglate group and 9.1% in the iodixanol group (P = 0.07). There were no significant differences in the rates of myocardial infarction (1.4% vs. 1.5%; P = 1.00) and repeated revascularization (6.8% vs. 9.1%; P = 0.75). Conclusions The use of ionic LOCM ioxaglate was associated with a numerically lower mortality at 1 year as compared to iodixanol in patients who underwent cardiac catheterization. Future studies evaluating long-term safety following exposure to different types of CM are warranted. © 2015 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text